Last reviewed · How we verify
Anti-pandemic H1N1 influenza vaccine
Anti-pandemic H1N1 influenza vaccine is a inactivated influenza vaccine Biologic drug developed by University of Sao Paulo. It is currently FDA-approved for Prevention of H1N1 influenza infection during pandemic periods.
The vaccine stimulates the immune system to produce antibodies and cellular immunity against H1N1 influenza virus antigens.
The vaccine stimulates the immune system to produce antibodies and cellular immunity against H1N1 influenza virus antigens. Used for Prevention of H1N1 influenza infection during pandemic periods.
At a glance
| Generic name | Anti-pandemic H1N1 influenza vaccine |
|---|---|
| Sponsor | University of Sao Paulo |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
This inactivated influenza vaccine contains viral antigens (typically hemagglutinin and neuraminidase from H1N1 strain) that trigger both humoral and cell-mediated immune responses. Upon vaccination, B cells produce neutralizing antibodies against the virus, while T cells develop memory to recognize and eliminate infected cells, providing protection against H1N1 infection.
Approved indications
- Prevention of H1N1 influenza infection during pandemic periods
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia
- Fatigue
- Headache
Key clinical trials
- Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff. (PHASE4)
- A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza (PHASE3)
- Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-pandemic H1N1 influenza vaccine CI brief — competitive landscape report
- Anti-pandemic H1N1 influenza vaccine updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI
Frequently asked questions about Anti-pandemic H1N1 influenza vaccine
What is Anti-pandemic H1N1 influenza vaccine?
How does Anti-pandemic H1N1 influenza vaccine work?
What is Anti-pandemic H1N1 influenza vaccine used for?
Who makes Anti-pandemic H1N1 influenza vaccine?
What drug class is Anti-pandemic H1N1 influenza vaccine in?
What development phase is Anti-pandemic H1N1 influenza vaccine in?
What are the side effects of Anti-pandemic H1N1 influenza vaccine?
Related
- Drug class: All inactivated influenza vaccine drugs
- Manufacturer: University of Sao Paulo — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of H1N1 influenza infection during pandemic periods
- Compare: Anti-pandemic H1N1 influenza vaccine vs similar drugs
- Pricing: Anti-pandemic H1N1 influenza vaccine cost, discount & access